Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its Phase 3 gene therapy candidate for Type ...

Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will ...

Charlie Smith. Poster exhibit. Case of Fetal Immature Trauma. The Southern Radiological Conference, Marriott's Grand Hotel, Resort and Spa, Point Clear, Alabama, January 25-27, 2013. Charlie Smith.

Company will provide an overview of the pritelivir clinical development program in two oral presentations including a comprehensive Phase 2 data overview Updated safety and pharmacokinetic results of ...

AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient ...

‒ Poster for GP2 Phase IIb clinical trial final efficacy analysis was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) today ‒ Phase IIb clinical trial was a prospective, ...

Calling all UMass Lowell students: present your research and scholarly work at the 2026 Student Research and Community Engagement Symposium on March 31, 2026! The first step to participate is to ...

Five presentations will showcase nizubaglustat's therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick ...